Bellicum reports second quarter 2022 financial results and provides operational update

Houston, aug. 11, 2022 (globe newswire) -- bellicum pharmaceuticals, inc. (nasdaq: blcm), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the second quarter 2022 and provided an operational update.
BLCM Ratings Summary
BLCM Quant Ranking